Full Press Release Details
Biotech Inc. Announces Details of 2009 Annual Shareholder Meeting
CALGARY, AB, --- April 30, 2009
--- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that
its 2009 Annual and Special Meeting of the Shareholders will be held on Tuesday, May 5, 2009 at 2:30 p.m. (MT)
at the Telus World of Science, 701-11 Street SW, Calgary.
the business portion of the meeting, Dr. Brad Thompson, President and CEO of
Oncolytics, will discuss recent progress in developing REOLYSIN as a potential
A live audio webcast of the
presentation will begin at approximately 2:45 p.m. (MT) at: http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2632960 or on the company's website
at www.oncolyticsbiotech.com. It is recommended that listeners log on
15 minutes in advance of the presentation to register and download any necessary
replay will be accessible following the presentation at www.oncolyticsbiotech.com.
Oncolytics Biotech Inc.
is a Calgary-based biotechnology company focused on the development of oncolytic
viruses as potential cancer therapeutics. Oncolytics' clinical
program includes a variety of Phase I/II and Phase II human trials using
REOLYSIN, its proprietary formulation of the human reovirus, alone and in
combination with radiation or chemotherapy. For further information about
Oncolytics, please visit www.oncolyticsbiotech.com
The presentation time is subject to
change. This release and the presentation related thereto contain
forward-looking statements which involve known and unknown risks, delays,
uncertainties and other factors not under the Company's control and which may
cause actual results, performance or achievements of the Company to be
materially different from the results, performance or expectations implied by
these forward-looking statements. Such risks and uncertainties include,
among others, the efficacy of REOLYSIN as a cancer treatment, the success and timely
completion of clinical studies and trials, uncertainties related to the research
and development of pharmaceuticals, uncertainties related to the regulatory
process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with
the Canadian and U.S. securities commissions for
additional information on risks and uncertainties relating to the
statements. Investors are cautioned against placing undue reliance on forward-looking statements. The
does not undertake to update these forward-looking statements except as required
FURTHER INFORMATION PLEASE CONTACT: